Видео ютуба по тегу Casdatifan

ARC-20: Casdatifan Plus Cabozantinib Expansion Cohort
ARC-20: Casdatifan Plus Cabozantinib Expansion Cohort
ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma
ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma
ARC-20: Casdatifan for Patients With Previously Treated ccRCC
ARC-20: Casdatifan for Patients With Previously Treated ccRCC
2025 ASCO Kidney Cancer Highlights
2025 ASCO Kidney Cancer Highlights
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
New and upcoming treatments for clear cell renal cell carcinoma
New and upcoming treatments for clear cell renal cell carcinoma
Toni Choueiri on casdatifan in kidney cancer: ENA24 | Dana-Farber Cancer Institute
Toni Choueiri on casdatifan in kidney cancer: ENA24 | Dana-Farber Cancer Institute
EA8143/PROSPER RCC Clinical Trial for Renal Cell Carcinoma
EA8143/PROSPER RCC Clinical Trial for Renal Cell Carcinoma
Evaluating the evolving role of belzutifan in renal cell carcinoma
Evaluating the evolving role of belzutifan in renal cell carcinoma
KCRS24 - Biotech Showcase on Emerging Therapies for Kidney Cancer | KidneyCAN
KCRS24 - Biotech Showcase on Emerging Therapies for Kidney Cancer | KidneyCAN
BCG, Biomarkers, and Beyond: GU Oncology Research and Treatment Advances
BCG, Biomarkers, and Beyond: GU Oncology Research and Treatment Advances
55% OS Boost in Urothelial Cancer with Enfortumab Vedotin + Pembrolizumab: Must-See ASCO Insights
55% OS Boost in Urothelial Cancer with Enfortumab Vedotin + Pembrolizumab: Must-See ASCO Insights
Immunology Update – December 17, 2025: ITP win, CAR T in SLE, First RDEB gene therapy and More
Immunology Update – December 17, 2025: ITP win, CAR T in SLE, First RDEB gene therapy and More
2026 год определит будущее персонализированной медицины: 12 важных клинических исследований.
2026 год определит будущее персонализированной медицины: 12 важных клинических исследований.
Biotech Showcase | Kidney Cancer Research Summit 2025
Biotech Showcase | Kidney Cancer Research Summit 2025
ASCO25: Toni Choueiri, MD, ARC-20 Study | Dana-Farber Cancer Institute
ASCO25: Toni Choueiri, MD, ARC-20 Study | Dana-Farber Cancer Institute
RCC trials at ASCO 2025: CheckMate 214, ARC-20, LITESPARK-004 and TRAVERSE
RCC trials at ASCO 2025: CheckMate 214, ARC-20, LITESPARK-004 and TRAVERSE
Oral Abstract Presentations | Kidney Cancer Research Summit 2025
Oral Abstract Presentations | Kidney Cancer Research Summit 2025